EGFR and non-small cell lung carcinoma: Based on the post hoc analysis of the LUX-Lung 2/3/6 trials (9, 20, 21), the treatment indication for afatinib has been expanded to the first-line treatment of metastatic NSCLC with non-resistant EGFR mutation including L861Q/G719X/S768I.